| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 01/02/2002 | CN1329493A Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 01/02/2002 | CN1329490A Composition and method for treating allergic diseases |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335348 Administering pipecolic acid derivative as cognition activator and to treat eye and nervous system disorders |
| 01/01/2002 | US6335343 Inhibitors of prenyl-protein transferase |
| 01/01/2002 | US6335332 Barbituric acid derivatives with antimetastatic and antitumor activity |
| 01/01/2002 | US6335329 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 01/01/2002 | US6335328 Process for the isolation of galanthamine |
| 01/01/2002 | US6335182 Recombinant Haemophilus influenzae adhesin proteins |
| 01/01/2002 | CA2235626C Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury |
| 01/01/2002 | CA2093789C Bi-aromatic compounds and their use in human and veterinary medicine and in cosmetic preparations |
| 12/27/2001 | WO2001098493A1 Insulin-like growth factor-binding protein |
| 12/27/2001 | WO2001098471A2 Human phosphodiesterases |
| 12/27/2001 | WO2001098362A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098334A2 Streptococcus antigens |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098297A2 A thiazine oxazolidinone |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | WO2001098289A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098270A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098269A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098268A2 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098256A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| 12/27/2001 | WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 12/27/2001 | WO2001021159A3 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 12/27/2001 | WO2000067626A3 Oat extracts: refining, compositions and methods of use |
| 12/27/2001 | US20010056184 Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds |
| 12/27/2001 | US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/27/2001 | US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12 |
| 12/27/2001 | US20010056104 Treatment of ocular hypertension and glaucoma by long-term therapy with a prostaglandin related compound for elimination or reduction of potential iridic pigmentation |
| 12/27/2001 | US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 12/27/2001 | US20010056093 Olopatadine and emedastine and an ophthalmically acceptable polymeric quaternary ammonium compound as a preservative |
| 12/27/2001 | US20010056092 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | CA2413450A1 Streptococcus antigens |
| 12/27/2001 | CA2413421A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | CA2413418A1 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | CA2413274A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2412215A1 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | CA2412011A1 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | CA2411585A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | CA2411236A1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | CA2410358A1 A thiazine oxazolidinone |
| 12/27/2001 | CA2409781A1 Phosphodiesterases |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/26/2001 | CN1328573A Cross-linked hyaluronic acids and medical uses thereof |
| 12/26/2001 | CN1328538A 2,4-pentadienoic acid derivatives having selective activity for retinoid X(RXR) receptors |
| 12/26/2001 | CN1328462A Use of staurosporine derivatives for treating ocular neovascular diseases |
| 12/26/2001 | CN1328461A Method for preventing/treating damage to sensory hair cells and cochlear neurons |
| 12/26/2001 | CN1327839A Eye-protecting eyedrops |
| 12/26/2001 | CN1076618C Liquid medicine for treating wound and pain and preparing process thereof |
| 12/25/2001 | US6333352 Method of treating benign positional vertigo |
| 12/25/2001 | US6333341 Tumor necrosis factor, antiinflammatory agents and analgesics |
| 12/25/2001 | US6333340 Sulfonamides with oxo, ester or amide groups for vision defects and cognition activators |
| 12/25/2001 | US6333035 Administering monoclonal antibody against a human t-cell leukemia virus-derived transcription activating factor p40tax-induced cell membrane glycoprotein of 34 kda (gp34) in an amount effective for treating rheumatoid arthritis |
| 12/25/2001 | CA2172779C Cgrp antagonist used for the treatment of pruritus and ocular or palpebral dysesthesia |
| 12/20/2001 | WO2001096547A2 Human kinases |
| 12/20/2001 | WO2001096546A2 Protein phosphatases |
| 12/20/2001 | WO2001096397A2 Cd154 variants and uses thereof |
| 12/20/2001 | WO2001096334A2 Heteroarylalkanoic acids as integrin receptor antagonists |
| 12/20/2001 | WO2001096310A1 Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
| 12/20/2001 | WO2001096307A2 Cycloalkyl alkanoic acids as integrin receptor antagonists |
| 12/20/2001 | WO2001096305A1 Serine protease inhibitors |
| 12/20/2001 | WO2001095928A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | WO2001095893A1 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095892A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095879A1 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 12/20/2001 | WO2001095878A1 Process for the preparation of a sterile ointment containing acyclovir |
| 12/20/2001 | WO2001058896A8 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 12/20/2001 | US20010053853 Alkanoic acid derivative; integrin receptor antagonist |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | CA2411472A1 Cd154 variants |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/20/2001 | CA2407699A1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/19/2001 | EP1164183A1 Solution for contact lenses |
| 12/19/2001 | EP1163904A1 Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium |
| 12/19/2001 | EP1163356A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites |
| 12/19/2001 | EP1163332A1 48 human secreted proteins |
| 12/19/2001 | EP1163274A1 Process for cross-linking hyaluronic acid to polymers |
| 12/19/2001 | EP1163270A1 Dihydroouabain-like factor and diagnostic and therapeutic compositions and methods |
| 12/19/2001 | EP1163255A1 50 human secreted proteins |
| 12/19/2001 | EP1163239A1 Modified amino-acid amides as cgrp antagonists |
| 12/19/2001 | EP1163226A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 12/19/2001 | EP1163225A1 Compounds and methods for modulation of estrogen receptors |
| 12/19/2001 | EP1163213A1 Hydroxamic and carboxylic acid derivatives |
| 12/19/2001 | EP1163005A1 Model and method for angiogenesis inhibition |
| 12/19/2001 | EP1163000A2 Vaccine against antigens from bacteriae |
| 12/19/2001 | EP1162999A2 Vaccine against Streptococcus pneumoniae |
| 12/19/2001 | EP1162998A2 Vaccine against streptococcus pneumoniae capsular polysaccharides |